A major NIH-funded study on COVID-19 immunity at Ohio State was terminated early, limiting insights crucial for next-generation vaccines and future outbreak response.
A major NIH-funded research program at The Ohio State University, part of the national Serological Sciences Network studying immune responses to COVID-19, was ended nearly six months before the end of its five-year award period. The program was designed to track how immunity to COVID-19 changes over time, using advanced lab methods to measure antibodies and other immune markers in blood and related samples. Researchers followed diverse groups of participants—including cancer patients and others with weakened immune systems—to better understand how protection from vaccination or prior infection holds up over time as the virus evolves. The program’s findings directly informed national vaccine policy, with data helping guide FDA decisions on updated COVID-19 vaccines to address emerging variants. In addition, researchers also built a large and unique collection of patient samples, creating a valuable resource for future studies on how early infections or vaccinations shape immune responses later on, and whether immunity to some viruses can offer partial protection against others. These insights could inform work not only on COVID-19 but also on influenza and other respiratory diseases.
The program’s early end left important lines of research unfinished, including studies on how immunity works in the nose and airways—knowledge that is key to developing next-generation vaccines that can stop infection at the point of entry, not just reduce illness. The loss of funding also led to significant staff and infrastructure impacts. The lab was forced to lay off half of its team, disrupting careers, especially for early-career researchers, and putting at risk the specialized expertise built during the pandemic. The research team also lost key collaborators who have since left US academia for positions overseas, reflecting broader challenges in sustaining US leadership in infectious disease research. At the same time, the program’s large collection of frozen samples is now at risk, as continued storage depends on funding. If these samples cannot be preserved, it will close off opportunities for future research and long-term tracking of immune responses to new variants.